{"id":"irinotecan-cetuximab","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Acneiform rash"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Irinotecan is a topoisomerase I inhibitor that causes DNA damage in rapidly dividing cancer cells. Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), which blocks growth signaling and enhances the efficacy of chemotherapy. The combination leverages synergistic effects in EGFR-expressing colorectal cancers.","oneSentence":"Irinotecan inhibits topoisomerase I to damage cancer cell DNA, while cetuximab blocks EGFR signaling to prevent tumor growth and enhance chemotherapy sensitivity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:02.135Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer, EGFR-positive or wild-type KRAS"},{"name":"Advanced colorectal cancer as first-line or later-line therapy"}]},"trialDetails":[{"nctId":"NCT05863195","phase":"PHASE3","title":"Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-10-19","conditions":"Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8","enrollment":408},{"nctId":"NCT06662786","phase":"PHASE3","title":"A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-10-18","conditions":"Colorectal Neoplasms","enrollment":1000},{"nctId":"NCT07474727","phase":"PHASE2","title":"A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Multitude Therapeutics Inc.","startDate":"2026-04-01","conditions":"Colorectal Cancer","enrollment":180},{"nctId":"NCT06607185","phase":"PHASE1","title":"A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-10-21","conditions":"Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer","enrollment":750},{"nctId":"NCT06011772","phase":"EARLY_PHASE1","title":"EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2023-12-18","conditions":"Colo-rectal Cancer","enrollment":2},{"nctId":"NCT05239741","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-04-02","conditions":"Colorectal Neoplasms","enrollment":100},{"nctId":"NCT05722327","phase":"PHASE1","title":"Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-12-06","conditions":"Colon Cancer, Colorectal Cancer","enrollment":24},{"nctId":"NCT04929223","phase":"PHASE1","title":"A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-22","conditions":"Metastatic Colorectal Cancer","enrollment":542},{"nctId":"NCT05382559","phase":"PHASE1","title":"A Study of ASP3082 in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2022-06-08","conditions":"Solid Tumor","enrollment":681},{"nctId":"NCT07415031","phase":"PHASE2","title":"A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies","status":"NOT_YET_RECRUITING","sponsor":"Mirati Therapeutics Inc.","startDate":"2026-05-16","conditions":"Solid Tumors","enrollment":170},{"nctId":"NCT06750094","phase":"PHASE3","title":"A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-12-12","conditions":"Colorectal Neoplasms","enrollment":700},{"nctId":"NCT03365882","phase":"PHASE2","title":"S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2017-11-27","conditions":"Colon Adenocarcinoma, ERBB2 Gene Amplification, Rectal Adenocarcinoma","enrollment":240},{"nctId":"NCT07391618","phase":"PHASE2","title":"Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-05-15","conditions":"Advanced Colorectal Cancer","enrollment":583},{"nctId":"NCT03693807","phase":"PHASE2","title":"A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-10-18","conditions":"Colorectal Cancer, Cholangiocarcinoma","enrollment":35},{"nctId":"NCT07389265","phase":"PHASE3","title":"Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2025-10-01","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":480},{"nctId":"NCT04587128","phase":"PHASE2","title":"Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2020-10-19","conditions":"Metastatic Colorectal Cancer","enrollment":34},{"nctId":"NCT00556413","phase":"PHASE2","title":"Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2005-09","conditions":"Colorectal Cancer","enrollment":42},{"nctId":"NCT06771622","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"FBD Biologics Limited","startDate":"2025-03-13","conditions":"Solid Cancer","enrollment":500},{"nctId":"NCT07381764","phase":"PHASE2","title":"ROMANCE: \"Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer\"","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico Italia Meridionale","startDate":"2026-03-30","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":150},{"nctId":"NCT06199232","phase":"NA","title":"Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking University","startDate":"2024-01-23","conditions":"Liver Metastasis Colon Cancer, ctDNA Genotype, MSS","enrollment":47},{"nctId":"NCT07353268","phase":"PHASE2","title":"Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy.","status":"NOT_YET_RECRUITING","sponsor":"Tao Zhang","startDate":"2026-01-21","conditions":"Colorectal Cancer","enrollment":76},{"nctId":"NCT07094893","phase":"PHASE4","title":"Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2026-04-15","conditions":"Colorectal Cancer","enrollment":280},{"nctId":"NCT03366155","phase":"PHASE2","title":"Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-24","conditions":"Colorectal Cancer, Liver Metastases, Colorectal Adenocarcinoma","enrollment":24},{"nctId":"NCT03290937","phase":"PHASE1","title":"Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-12-27","conditions":"Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8","enrollment":34},{"nctId":"NCT07309289","phase":"PHASE3","title":"NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-07-01","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":144},{"nctId":"NCT03803553","phase":"PHASE3","title":"Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-04-16","conditions":"Metastatic Colon Cancer, Stage III Colon Cancer","enrollment":400},{"nctId":"NCT06586515","phase":"PHASE1","title":"MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-09-12","conditions":"Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer","enrollment":630},{"nctId":"NCT06540326","phase":"PHASE2","title":"Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-11-12","conditions":"Colorectal Cancer Metastatic","enrollment":100},{"nctId":"NCT05959356","phase":"PHASE2","title":"Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-11-09","conditions":"Metastatic Colorectal Cancer","enrollment":198},{"nctId":"NCT04008030","phase":"PHASE3","title":"A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2019-08-05","conditions":"Metastatic Colorectal Cancer","enrollment":839},{"nctId":"NCT07204574","phase":"PHASE1, PHASE2","title":"The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2025-05-14","conditions":"CRC","enrollment":40},{"nctId":"NCT04776655","phase":"PHASE3","title":"Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB","status":"RECRUITING","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"2021-04-30","conditions":"Colorectal Cancer, Metastatic Colorectal Cancer, RAS Mutation","enrollment":280},{"nctId":"NCT06967155","phase":"PHASE2","title":"A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2025-03-01","conditions":"Neoplasms","enrollment":23},{"nctId":"NCT05104567","phase":"PHASE2","title":"A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-12-09","conditions":"Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma","enrollment":138},{"nctId":"NCT07183865","phase":"PHASE2","title":"Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-03-09","conditions":"Locally Recurrent Rectal Cancer","enrollment":44},{"nctId":"NCT01787500","phase":"PHASE1","title":"Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-02-15","conditions":"BRAF NP_004324.2:p.V600X, KRAS wt Allele, Metastatic Malignant Solid Neoplasm","enrollment":33},{"nctId":"NCT04607421","phase":"PHASE3","title":"A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-12-21","conditions":"Neoplasms","enrollment":831},{"nctId":"NCT03493048","phase":"PHASE2","title":"Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-04-15","conditions":"Colorectal Cancer, Liver Metastases","enrollment":146},{"nctId":"NCT07070713","phase":"PHASE2","title":"Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-07-30","conditions":"Metastatic Colorectal Cancer With Left-sided Primary Tumor, Immunotherapy","enrollment":44},{"nctId":"NCT07059338","phase":"PHASE2","title":"Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-07-11","conditions":"HER2 Positive, Colorectal Cancer (CRC)","enrollment":34},{"nctId":"NCT07044921","phase":"PHASE2","title":"Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer.","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2024-09-01","conditions":"Colorectal Cancer Metastatic","enrollment":30},{"nctId":"NCT03186326","phase":"PHASE2","title":"Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2018-04-24","conditions":"Metastatic Colorectal Cancer, MSI","enrollment":132},{"nctId":"NCT04554836","phase":"PHASE2","title":"MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab","status":"COMPLETED","sponsor":"TheraOp","startDate":"2020-12-29","conditions":"Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum","enrollment":6},{"nctId":"NCT07004413","phase":"PHASE3","title":"Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients","status":"NOT_YET_RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2026-01-01","conditions":"Colorectal Cancer Metastatic","enrollment":267},{"nctId":"NCT05312398","phase":"PHASE2","title":"CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2021-07-15","conditions":"Metastatic Colorectal Adenocarcinoma","enrollment":219},{"nctId":"NCT04495621","phase":"PHASE1, PHASE2","title":"MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)","status":"COMPLETED","sponsor":"Menarini Group","startDate":"2020-07-20","conditions":"Metastatic Colorectal Cancer","enrollment":29},{"nctId":"NCT03428958","phase":"PHASE1, PHASE2","title":"A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment","status":"COMPLETED","sponsor":"NuCana plc","startDate":"2018-10-05","conditions":"Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma","enrollment":111},{"nctId":"NCT02934529","phase":"PHASE3","title":"Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2015-03","conditions":"Metastatic Colorectal Cancer","enrollment":673},{"nctId":"NCT05217069","phase":"PHASE2","title":"FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2019-09-27","conditions":"Treatment Related Cancer","enrollment":57},{"nctId":"NCT05004350","phase":"PHASE2","title":"A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","startDate":"2021-09-14","conditions":"BRAF V600E, Metastatic Colorectal Cancer","enrollment":107},{"nctId":"NCT06928584","phase":"PHASE2","title":"Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-03-10","conditions":"Locally Recurrent Rectal Cancer","enrollment":221},{"nctId":"NCT00545545","phase":"PHASE1, PHASE2","title":"Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma","status":"COMPLETED","sponsor":"HiberCell, Inc.","startDate":"2007-10","conditions":"Recurrent Colorectal Carcinoma, Progressive Colorectal Carcinoma","enrollment":32},{"nctId":"NCT06763029","phase":"PHASE2","title":"Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-02-26","conditions":"Colorectal Cancer Metastatic","enrollment":36},{"nctId":"NCT06841159","phase":"PHASE2","title":"Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-03-01","conditions":"Microsatellite Stable Metastatic Colorectal Cancer","enrollment":116},{"nctId":"NCT06833866","phase":"PHASE1","title":"Phase I Trial of 5-Fluorouracil (5FU) -Based Therapy in Combination With Hydroxytyrosol (HT) in Patients With Advanced or Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2024-12-04","conditions":"Advanced or Metastatic CRC","enrollment":33},{"nctId":"NCT06640166","phase":"PHASE2","title":"Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2024-06-03","conditions":"Colorectal Carcinoma, Colorectal Neoplasms, Colorectal Tumor","enrollment":25},{"nctId":"NCT04793958","phase":"PHASE3","title":"Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mirati Therapeutics Inc.","startDate":"2021-06-24","conditions":"Advanced Colorectal Cancer, Metastatic Colorectal Cancer","enrollment":461},{"nctId":"NCT01878422","phase":"PHASE3","title":"Sequential Treatment Strategy for Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2007-11","conditions":"Metastatic Colorectal Cancer","enrollment":376},{"nctId":"NCT00248287","phase":"PHASE2","title":"PhII ICb With/Without Erbitux in MBC Pts","status":"ACTIVE_NOT_RECRUITING","sponsor":"US Oncology Research","startDate":"2005-07-28","conditions":"Metastatic Breast Cancer","enrollment":154},{"nctId":"NCT04513951","phase":"PHASE2","title":"AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients","status":"COMPLETED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2020-04-01","conditions":"Metastatic Colorectal Cancer","enrollment":62},{"nctId":"NCT01167725","phase":"PHASE3","title":"Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2010-08","conditions":"Colorectal Cancer","enrollment":340},{"nctId":"NCT04687631","phase":"PHASE3","title":"Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases","status":"RECRUITING","sponsor":"Fudan University","startDate":"2021-01-14","conditions":"Colorectal Cancer, Liver Metastases","enrollment":508},{"nctId":"NCT03009058","phase":"PHASE1, PHASE2","title":"Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer","status":"TERMINATED","sponsor":"Immodulon Therapeutics Ltd","startDate":"2017-05-31","conditions":"Metastatic Cancer","enrollment":2},{"nctId":"NCT03874026","phase":"PHASE2","title":"Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients","status":"RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2019-09-05","conditions":"Colorectal Cancer, ADCC","enrollment":34},{"nctId":"NCT05424692","phase":"NA","title":"Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2021-09-01","conditions":"Colon Cancer, Rectal Cancer, Chemotherapy Effect","enrollment":200},{"nctId":"NCT02563002","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-11-30","conditions":"Colorectal Carcinoma","enrollment":307},{"nctId":"NCT03164655","phase":"PHASE2","title":"Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2018-07-25","conditions":"Colorectal Cancer Metastatic","enrollment":20},{"nctId":"NCT05628038","phase":"PHASE2","title":"The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-11-30","conditions":"Recurrent Rectal Cancer","enrollment":93},{"nctId":"NCT04117945","phase":"PHASE2","title":"Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2020-03-03","conditions":"BRAF V600E Negative, KRAS Gene Mutation Negative, Locally Advanced Unresectable Colorectal Adenocarcinoma","enrollment":22},{"nctId":"NCT06603376","phase":"PHASE2","title":"Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2024-09-01","conditions":"Colorectal Carcinoma","enrollment":75},{"nctId":"NCT06575127","phase":"PHASE2","title":"Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study","status":"RECRUITING","sponsor":"Al-Azhar University","startDate":"2024-08-17","conditions":"Neoplasm Malignant, Colon Cancer Stage 4","enrollment":60},{"nctId":"NCT06547203","phase":"PHASE2","title":"Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-07-18","conditions":"Colorectal Cancer Metastatic","enrollment":34},{"nctId":"NCT06525428","phase":"PHASE2","title":"Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-04-01","conditions":"Microsatellite Stable Metastatic Colorectal Cancer","enrollment":96},{"nctId":"NCT05189171","phase":"","title":"MicroOrganoSphere (MOS) Drug Screen Pilot Trial in Colorectal Cancer","status":"COMPLETED","sponsor":"Xilis, Inc.","startDate":"2022-10-25","conditions":"Colorectal Neoplasms","enrollment":46},{"nctId":"NCT06322147","phase":"","title":"Chemotherapy With Cetuximab as Conversion Therapy in RAS/BRAF WT Unresectable Liver Metastasis Right-sided Colon Cancer","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2023-06-01","conditions":"Colon Cancer","enrollment":50},{"nctId":"NCT06321081","phase":"PHASE2","title":"ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC","status":"RECRUITING","sponsor":"Beijing Hospital","startDate":"2024-03-01","conditions":"RAS Mutation, Metastatic Colorectal Cancer, MSS","enrollment":60},{"nctId":"NCT06225622","phase":"PHASE1","title":"Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-03-11","conditions":"Metastatic Colorectal Cancer","enrollment":78},{"nctId":"NCT01910610","phase":"PHASE3","title":"Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2013-10-30","conditions":"Colorectal Cancer Metastatic","enrollment":464},{"nctId":"NCT02928224","phase":"PHASE3","title":"Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-10-13","conditions":"BRAF V600E-mutant Metastatic Colorectal Cancer","enrollment":702},{"nctId":"NCT03485027","phase":"PHASE2","title":"Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Fudan University","startDate":"2018-01-24","conditions":"Metastatic Colorectal Cancer, Chemotherapy Effect","enrollment":43},{"nctId":"NCT04034459","phase":"PHASE2","title":"FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC","status":"UNKNOWN","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2016-11-25","conditions":"Metastatic Colorectal Cancer","enrollment":109},{"nctId":"NCT03914170","phase":"","title":"Folfirinox + Cetuximab Chemotherapy, in First Line, With Wild RAS and According to BRAF Status in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2017-04-01","conditions":"Colorectal Cancer","enrollment":70},{"nctId":"NCT05962502","phase":"PHASE2","title":"Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-08-24","conditions":"Metastatic Colorectal Cancer","enrollment":54},{"nctId":"NCT05978349","phase":"NA","title":"PTC Drug Sensitivity Detection to Guide Postoperative Adjuvant of Colorectal Cancer","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2022-02-14","conditions":"Colo-rectal Cancer","enrollment":150},{"nctId":"NCT00677924","phase":"PHASE1, PHASE2","title":"Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer","status":"TERMINATED","sponsor":"Genmab","startDate":"2008-04","conditions":"Colorectal Cancer","enrollment":9},{"nctId":"NCT00042939","phase":"PHASE2","title":"Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2003-12-09","conditions":"Pancreatic Cancer","enrollment":94},{"nctId":"NCT01079780","phase":"PHASE2","title":"Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2011-01-18","conditions":"Colorectal Cancer","enrollment":136},{"nctId":"NCT04189055","phase":"PHASE2","title":"Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases.","status":"UNKNOWN","sponsor":"Hôpital Franco-Britannique-Fondation Cognacq-Jay","startDate":"2020-01-07","conditions":"Cancer Colorectal","enrollment":72},{"nctId":"NCT05160896","phase":"PHASE2","title":"SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-11-12","conditions":"Advanced Metastatic Colorectal Cancer","enrollment":90},{"nctId":"NCT05799443","phase":"PHASE2","title":"Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2023-04-05","conditions":"Colorectal Cancer","enrollment":23},{"nctId":"NCT03391934","phase":"PHASE3","title":"Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Cinnagen","startDate":"2018-01-20","conditions":"Metastatic Colorectal Cancer","enrollment":234},{"nctId":"NCT05797883","phase":"PHASE2","title":"FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"China Medical University, China","startDate":"2022-08-01","conditions":"Unresectable or Metastatic Colorectal Cancer","enrollment":30},{"nctId":"NCT05278351","phase":"PHASE2","title":"Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2022-07-13","conditions":"Colorectal Neoplasms Malignant","enrollment":87},{"nctId":"NCT05143099","phase":"PHASE2","title":"Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory mCRC","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-02-01","conditions":"Colorectal Neoplasms","enrollment":35},{"nctId":"NCT04224415","phase":"PHASE2","title":"Re-challenge of Anti-EGFR for Patients With RAS/BRAF Wild-type Metastatic CRC","status":"COMPLETED","sponsor":"Yuhong Li","startDate":"2020-01-31","conditions":"Metastatic Colorectal Cancer","enrollment":35},{"nctId":"NCT04790448","phase":"PHASE1, PHASE2","title":"Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2020-07-27","conditions":"Colorectal Cancer Metastatic","enrollment":37},{"nctId":"NCT03251612","phase":"PHASE2","title":"Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Vejle Hospital","startDate":"2017-09-22","conditions":"Colorectal Cancer Metastatic","enrollment":90},{"nctId":"NCT05652894","phase":"PHASE3","title":"A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Taizhou Hanzhong biomedical co. LTD","startDate":"2022-12-20","conditions":"Metastatic Colorectal Cancer","enrollment":190},{"nctId":"NCT00954876","phase":"PHASE2","title":"Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer","status":"WITHDRAWN","sponsor":"Translational Genomics Research Institute","startDate":"2009-08","conditions":"Metastatic Colorectal Cancer","enrollment":""},{"nctId":"NCT05540951","phase":"PHASE3","title":"VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2018-06-01","conditions":"Colorectal Cancer","enrollment":78}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":49,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CPT11/Cetuximab"],"phase":"phase_3","status":"active","brandName":"Irinotecan/Cetuximab","genericName":"Irinotecan/Cetuximab","companyName":"Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente","companyId":"gruppo-italiano-per-lo-studio-dei-carcinomi-dell-apparato-digerente","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Irinotecan inhibits topoisomerase I to damage cancer cell DNA, while cetuximab blocks EGFR signaling to prevent tumor growth and enhance chemotherapy sensitivity. Used for Metastatic colorectal cancer, EGFR-positive or wild-type KRAS, Advanced colorectal cancer as first-line or later-line therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}